Homozygous Familial Hypercholesterolemia (HoFH) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Homozygous Familial Hypercholesterolemia (HoFH) – Pipeline Review, H1 2017’, provides an overview of the Homozygous Familial Hypercholesterolemia (HoFH) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Homozygous Familial Hypercholesterolemia (HoFH) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Homozygous Familial Hypercholesterolemia (HoFH)

– The report reviews pipeline therapeutics for Homozygous Familial Hypercholesterolemia (HoFH) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Homozygous Familial Hypercholesterolemia (HoFH) therapeutics and enlists all their major and minor projects

– The report assesses Homozygous Familial Hypercholesterolemia (HoFH) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Homozygous Familial Hypercholesterolemia (HoFH)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Homozygous Familial Hypercholesterolemia (HoFH) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

CymaBay Therapeutics Inc

Daewoong Co Ltd

Gemphire Therapeutics Inc

LipimetiX Development Inc

Regeneron Pharmaceuticals Inc

RegenxBio Inc

The Medicines Company

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Homozygous Familial Hypercholesterolemia (HoFH) - Overview

Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Homozygous Familial Hypercholesterolemia (HoFH) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Homozygous Familial Hypercholesterolemia (HoFH) - Companies Involved in Therapeutics Development

CymaBay Therapeutics Inc

Daewoong Co Ltd

Gemphire Therapeutics Inc

LipimetiX Development Inc

Regeneron Pharmaceuticals Inc

RegenxBio Inc

The Medicines Company

Homozygous Familial Hypercholesterolemia (HoFH) - Drug Profiles

AEM-28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AEM-2802 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AEM-2814 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alirocumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

evinacumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gemcabene calcium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

inclisiran - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGL-3196 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGL-3745 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RGX-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seladelpar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Homozygous Familial Hypercholesterolemia (HoFH) - Dormant Projects

Homozygous Familial Hypercholesterolemia (HoFH) - Product Development Milestones

Featured News & Press Releases

Apr 06, 2017: Regeneron Announces Evinacumab has Received FDA Breakthrough Therapy Designation for Homozygous Familial Hypercholesterolemia

Mar 14, 2017: The Medicines Company to Webcast Presentation of ORION-1 Phase II Study of Inclisiran at ACC.17

Jan 30, 2017: Gemphire Announces Interim LDL-C Lowering Data from COBALT-1 Phase 2b Clinical Trial

Jan 05, 2017: Gemphire Therapeutics Provides Clinical Update

Dec 19, 2016: Capstone Therapeutics Announces Profound, Rapid LDL Cholesterol Reduction in AEM-28-14 Primate Study

Sep 26, 2016: Gemphire Therapeutics Enrolls First Patient in the COBALT-1 Trial Investigating Gemcabene in Homozygous Familial Hypercholesterolemia

May 31, 2016: Regeneron Presents Positive Interim Data from Phase 2 Proof-of-Concept Study of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

Mar 17, 2016: CymaBay Therapeutics Announces Positive Results from its Pilot Phase 2 Clinical Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia

Apr 23, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Homozygous Familial Hypercholesterolemia

Mar 25, 2015: CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Homozygous Familial Hypercholesterolemia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Homozygous Familial Hypercholesterolemia (HoFH), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Homozygous Familial Hypercholesterolemia (HoFH) – Pipeline by CymaBay Therapeutics Inc, H1 2017

Homozygous Familial Hypercholesterolemia (HoFH) – Pipeline by Daewoong Co Ltd, H1 2017

Homozygous Familial Hypercholesterolemia (HoFH) – Pipeline by Gemphire Therapeutics Inc, H1 2017

Homozygous Familial Hypercholesterolemia (HoFH) – Pipeline by LipimetiX Development Inc, H1 2017

Homozygous Familial Hypercholesterolemia (HoFH) – Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Homozygous Familial Hypercholesterolemia (HoFH) – Pipeline by RegenxBio Inc, H1 2017

Homozygous Familial Hypercholesterolemia (HoFH) – Pipeline by The Medicines Company, H1 2017

Homozygous Familial Hypercholesterolemia (HoFH) – Dormant Projects, H1 2017

List of Figures

List of Figures

Number of Products under Development for Homozygous Familial Hypercholesterolemia (HoFH), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports